THE US Food and Drug Administration has announced the approval of Zejula (niraparib) for maintenance treatment, intended to delay cancer growth, for adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
THE Productivity Commission has recommended prioritising prevention programs to combat chronic conditions in its interim report, Delivering quality care more efficiently, a position welcomed by public health and patient peak bodies.
CSL has released its FY2025 results, with the company recording a “strong performance”, with 5% revenue growth and a 17% increase in net profit after tax for the year.
WHOLELIFE Pharmacy & Healthfoods honoured the outstanding achievements of its people and partners at its annual WholeLife Awards Dinner, held at Crown Sydney as part of the 2025 WholeLife Conference (PD 19 Aug).
Notifications
